Europe Fluorescent in Situ Hybridization (FISH) Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Europe Fluorescent in Situ Hybridization (FISH) market is projected to register a CAGR of 7.5% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Europe Fluorescent in Situ Hybridization (FISH) Market, By Product Type (Consumables, Instrument, and Software), Technology (DNA Fluorescent in Situ Hybridization, RNA Fluorescent in Situ Hybridization, PNA Fluorescent in Situ Hybridization, and Others), Application (Cancer Research, Genetic Research, Infectious Disease, Personalized Medicine, and Other), Usage (Clinical, Research, and Companion Diagnostic), End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceuticals & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, and Others), Distribution Channel (Retail Sales, Direct Tender, Online Sales, and Others), Country (Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, and Rest of Europe) - Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Europe Fluorescent in Situ Hybridization (FISH) market are:

Growing demand for better quality healthcare for genetic disorders and the rising adoption of personalized medicine

Increasing use of the FISH technique due to the rise in patients with breast cancer and other chronic diseases

Market Players

Some of the major market players operating in the Europe Fluorescent in Situ Hybridization (FISH) market are:

Thermo Fisher Scientific Inc.

Bio-Techne

Abbott

Agilent Technologies, Inc.

Merck KGaA

F. Hoffmann-La Roche Ltd

BIOZOL Diagnostics Vertrieb GmbH

Zytomed Systems GmbH

Genemed Biotechnologies, Inc.

Bio SB

BioGenex

BioCat GmbH

Leica Biosystems Nussloch GmbH

1 INTRODUCTION 38

1.1 OBJECTIVES OF THE STUDY 38
1.2 MARKET DEFINITION 38
1.3 OVERVIEW 38
1.4 CURRENCY AND PRICING 40
1.5 LIMITATIONS 40
1.6 MARKETS COVERED 41

2 MARKET SEGMENTATION 44

2.1 MARKETS COVERED 44
2.2 GEOGRAPHICAL SCOPE 45
2.3 YEARS CONSIDERED FOR THE STUDY 46
2.4 DBMR TRIPOD DATA VALIDATION MODEL 47
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.6 MULTIVARIATE MODELLING 51
2.7 MARKET APPLICATION COVERAGE GRID 52
2.8 PRODUCT LIFELINE CURVE 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 56
2.11 SECONDARY SOURCES 57
2.12 ASSUMPTIONS 57

3 EXECUTIVE SUMMARY 58

4 PREMIUM INSIGHTS 61

4.1 PORTER'S FIVE FORCES 62
4.2 PESTEL ANALYSIS 63
4.3 INDUSTRY INSIGHTS 64
4.4 CONCLUSION 65

5 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: REGULATORY FRAMEWORK 66

6 MARKET OVERVIEW 68

6.1 DRIVERS 70
- 6.1.1 GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER 70
- 6.1.2 INNOVATION AND ADVANCEMENTS IN FISH PRODUCTS 70
- 6.1.3 HIGH FUNDING FOR RESEARCH ACTIVITIES 71
- 6.1.4 RISING DEMAND AND USAGE OF FISH TECHNIQUES 71
6.2 RESTRAINTS 72
- 6.2.1 HIGH COST OF FISH TESTING 72
- 6.2.2 LIMITED AVAILABILITY OF SKILLED PROFESSIONALS 72
6.3 OPPORTUNITIES 73
- 6.3.1 RISING PUBLIC AWARENESS ABOUT THE EARLY DETECTION OF GENETIC ABNORMALITIES 73
- 6.3.2 RISE IN DEVELOPMENT OF SPECIFIC BIOMARKERS AND VARIOUS PROBES 73
6.4 CHALLENGES 74
- 6.4.1 STRINGENT GOVERNMENT REGULATIONS FOR THE APPROVAL OF FISH PROBES 74
- 6.4.2 ETHICAL CONCERNS ASSOCIATED WITH FISH TECHNOLOGY 74

7 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE 75

7.1 OVERVIEW 76
7.2 CONSUMABLES 79
- 7.2.1 FISH PROBE 79
  - 7.2.1.1 FISH PROBE, BY PROBE TYPE 80
    - 7.2.1.1.1 CHROMOSOME FISH PROBE 80
    - 7.2.1.1.2 SPLIT FISH PROBES 80
    - 7.2.1.1.3 TRANSLOCATION FISH PROBES 80
    - 7.2.1.1.4 SUBTELOMERE FISH PROBES 80
    - 7.2.1.1.5 PRENATAL FISH PROBES 80
    - 7.2.1.1.6 OTHERS PROBES 81
  - 7.2.1.2 FISH PROBE, BY TECHNOLOGY 81
    - 7.2.1.2.1 FLOW FLUORESCENT IN SITU HYBRIDIZATION 81
    - 7.2.1.2.2 C-ISH 81
    - 7.2.1.2.3 D-ISH 81
    - 7.2.1.2.4 Q- FLUORESCENT IN SITU HYBRIDIZATION 81
    - 7.2.1.2.5 OTHERS 81
  - 7.2.1.3 FISH PROBE, BY TYPE 82
    - 7.2.1.3.1 RNA 82
    - 7.2.1.3.1.1 MRNA 82
    - 7.2.1.3.1.2 MIRNA 82
    - 7.2.1.3.1.3 OTHERS 83
    - 7.2.1.3.2 DNA 83
- 7.2.2 ACCESSORY KITS & REAGENTS 83
  - 7.2.2.1 KITS 83
  - 7.2.2.2 BUFFER 83
  - 7.2.2.3 DYES 83
  - 7.2.2.4 OTHERS 84
7.3 INSTRUMENT 84
- 7.3.1 STANDALONE 85
- 7.3.2 PORTABLE 85
- 7.3.3 HANDHELD 85
7.4 SOFTWARE 85

8 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY 86

8.1 OVERVIEW 87
8.2 RNA FLUORESCENT IN SITU HYBRIDIZATION 90
8.3 DNA FLUORESCENT IN SITU HYBRIDIZATION 91
8.4 PNA FLUORESCENT IN SITU HYBRIDIZATION 92
8.5 OTHERS 93

9 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION 94

9.1 OVERVIEW 95
9.2 CANCER RESEARCH 98
- 9.2.1 CANCER RESEARCH, BY CANCER TYPE 99
  - 9.2.1.1 NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) 99
    - 9.2.1.1.1 BREAST CANCER 99
    - 9.2.1.1.2 LUNG CANCER 99
    - 9.2.1.1.3 MELANOMA 100
    - 9.2.1.1.4 PROSTRATE CANCER 100
    - 9.2.1.1.5 OVARIAN CANCER 100
    - 9.2.1.1.6 OTHERS 100
  - 9.2.1.2 HEMATOPOETIC MALIGNANCIES 100
    - 9.2.1.2.1 LEUKEMIA 100
    - 9.2.1.2.2 MULTIPLE MYELOMA 101
    - 9.2.1.2.3 MYELODYSPLASTIC SYNDROMES (MDS) 101
- 9.2.2 CANCER RESEARCH, BY PRODUCT 101
  - 9.2.2.1 CONSUMABLES 101
  - 9.2.2.2 INSTRUMENTS 101
  - 9.2.2.3 SOFTWARE 101
9.3 GENETIC RESEARCH 102
- 9.3.1 CYTOGENETICS 103
- 9.3.2 CHROMOSOMAL ABNORMALITIES 103
- 9.3.3 OTHERS 103
9.4 INFECTIOUS DISEASE 103
- 9.4.1 CONSUMABLES 104
- 9.4.2 INSTRUMENTS 104
- 9.4.3 SOFTWARE 104
9.5 PERSONALIZED MEDICINE 104
9.6 OTHERS 105

10 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE 106

10.1 OVERVIEW 107
10.2 RESEARCH 110
- 10.2.1 INSTRUMENTS 110
- 10.2.2 CONSUMABLES 111
- 10.2.3 SOFTWARE 111
10.3 CLINICAL 111
- 10.3.1 CONSUMABLES 112
- 10.3.2 INSTRUMENT 112
- 10.3.3 SOFTWARE 112
10.4 COMPANION DIAGNOSTIC 112
- 10.4.1 CONSUMABLES 113
- 10.4.2 INSTRUMENT 113
- 10.4.3 SOFTWARE 113

11 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER 114

11.1 OVERVIEW 115
11.2 DIAGNOSTIC LABORATORIES 118
11.3 HOSPITALS & CLINICS 118
11.4 PHARMACEUTICALS & BIOTECHNOLOGICAL COMPANIES 119
11.5 ACADEMIC & RESEARCH INSTITUTES 120
11.6 CONTRACT RESEARCH ORGANIZATIONS 120
11.7 OTHERS 121

12 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL 122

12.1 OVERVIEW 123
12.2 RETAIL SALES 126
12.3 ONLINE SALES 126
12.4 DIRECT TENDER 127
12.5 OTHERS 128

13 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION 129

13.1 EUROPE 130
- 13.1.1 GERMANY 144
- 13.1.2 U.K. 152
- 13.1.3 ITALY 160
- 13.1.4 FRANCE 168
- 13.1.5 SPAIN 176
- 13.1.6 RUSSIA 184
- 13.1.7 SWITZERLAND 192
- 13.1.8 TURKEY 200
- 13.1.9 BELGIUM 208
- 13.1.10 NETHERLANDS 216
- 13.1.11 DENMARK 224
- 13.1.12 SWEDEN 232
- 13.1.13 POLAND 240
- 13.1.14 NORWAY 248
- 13.1.15 FINLAND 256
- 13.1.16 REST OF EUROPE 264

14 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, COMPANY LANDSCAPE 265

14.1 COMPANY SHARE ANALYSIS: EUROPE 265

15 SWOT ANALYSIS 266

16 COMPANY PROFILE 267

16.1 MERCK KGAA 267
- 16.1.1 COMPANY SNAPSHOT 267
- 16.1.2 REVENUE ANALYSIS 267
- 16.1.3 COMPANY SHARE ANALYSIS 268
- 16.1.4 PRODUCT PORTFOLIO 268
- 16.1.5 RECENT DEVELOPMENT 268
16.2 ABBOTT 269
- 16.2.1 COMPANY SNAPSHOT 269
- 16.2.2 REVENUE ANALYSIS 269
- 16.2.3 COMPANY SHARE ANALYSIS 270
- 16.2.4 PRODUCT PORTFOLIO 270
- 16.2.5 RECENT DEVELOPMENT 271
16.3 AGILENT TECHNOLOGIES, INC. 272
- 16.3.1 COMPANY SNAPSHOT 272
- 16.3.2 REVENUE ANALYSIS 272
- 16.3.3 COMPANY SHARE ANALYSIS 273
- 16.3.4 PRODUCT PORTFOLIO 273
- 16.3.5 RECENT DEVELOPMENT 273
16.4 F. HOFFMANN-LA ROCHE LTD. 274
- 16.4.1 COMPANY SNAPSHOT 274
- 16.4.2 REVENUE ANALYSIS 274
- 16.4.3 COMPANY SHARE ANALYSIS 275
- 16.4.4 PRODUCT PORTFOLIO 275
- 16.4.5 RECENT DEVELOPMENT 275
16.5 THERMO FISCHER SCIENTIFIC INC. 276
- 16.5.1 COMPANY SNAPSHOT 276
- 16.5.2 REVENUE ANALYSIS 276
- 16.5.3 COMPANY SHARE ANALYSIS 277
- 16.5.4 PRODUCT PORTFOLIO 277
- 16.5.5 RECENT DEVELOPMENT 278
16.6 ABCAM PLC. 279
- 16.6.1 COMPANY SNAPSHOT 279
- 16.6.2 REVENUE ANALYSIS 279
- 16.6.3 COMPANY SHARE ANALYSIS 280
- 16.6.4 PRODUCT PORTFOLIO 280
- 16.6.5 RECENT DEVELOPMENTS 280
16.7 ABNOVA CORPORATION 282
- 16.7.1 COMPANY SNAPSHOT 282
- 16.7.2 PRODUCT PORTFOLIO 282
- 16.7.3 RECENT DEVELOPMENT 282
16.8 BIO SB 283
- 16.8.1 COMPANY SNAPSHOT 283
- 16.8.2 PRODUCT PORTFOLIO 283
- 16.8.3 RECENT DEVELOPMENT 283
16.9 BIOCARE MEDICAL, LLC 284
- 16.9.1 COMPANY SNAPSHOT 284
- 16.9.2 PRODUCT PORTFOLIO 284
- 16.9.3 RECENT DEVELOPMENT 285
16.10 BIOCAT GMBH 286
- 16.10.1 COMPANY SNAPSHOT 286
- 16.10.2 PRODUCT PORTFOLIO 286
- 16.10.3 RECENT DEVELOPMENT 287
16.11 BIODOT 288
- 16.11.1 COMPANY SNAPSHOT 288
- 16.11.2 PRODUCT PORTFOLIO 288
- 16.11.3 RECENT DEVELOPMENT 288
16.12 BIOGENEX 289
- 16.12.1 COMPANY SNAPSHOT 289
- 16.12.2 PRODUCT PORTFOLIO 289
- 16.12.3 RECENT DEVELOPMENT 289
16.13 BIO-TECHNE 290
- 16.13.1 COMPANY SNAPSHOT 290
- 16.13.2 REVENUE ANALYSIS 290
- 16.13.3 COMPANY SHARE ANALYSIS 291
- 16.13.4 PRODUCT PORTFOLIO 291
- 16.13.5 RECENT DEVELOPMENT 291
16.14 BIOZOL DIAGNOSTICS VERTRIEB GMBH 292
- 16.14.1 COMPANY SNAPSHOT 292
- 16.14.2 PRODUCT PORTFOLIO 292
- 16.14.3 RECENT DEVELOPMENT 293
16.15 EXCILONE 294
- 16.15.1 COMPANY SNAPSHOT 294
- 16.15.2 PRODUCT PORTFOLIO 294
- 16.15.3 RECENT DEVELOPMENT 294
16.16 GENEMED BIOTECHNOLOGIES, INC. 295
- 16.16.1 COMPANY SNAPSHOT 295
- 16.16.2 PRODUCT PORTFOLIO 295
- 16.16.3 RECENT DEVELOPMENT 295
16.17 KANEKA EUROGENTEC S.A. 296
- 16.17.1 COMPANY SNAPSHOT 296
- 16.17.2 PRODUCT PORTFOLIO 296
- 16.17.3 RECENT DEVELOPMENT 296
16.18 LEICA BIOSYSTEMS NUSSLOCH GMBH 297
- 16.18.1 COMPANY SNAPSHOT 297
- 16.18.2 PRODUCT PORTFOLIO 297
- 16.18.3 RECENT DEVELOPMENT 297
16.19 METASYSTEMS 298
- 16.19.1 COMPANY SNAPSHOT 298
- 16.19.2 PRODUCT PORTFOLIO 298
- 16.19.3 RECENT DEVELOPMENT 298

16.20 SYSMEX ASIA PACIFIC PTE LTD (A SUBSIDIARY OF SYSMEX CORPORATION) 299
- 16.20.1 COMPANY SNAPSHOT 299
- 16.20.2 REVENUE ANALYSIS 299
- 16.20.3 PRODUCT PORTFOLIO 300
- 16.20.4 RECENT DEVELOPMENT 300
16.21 ZYTOMED SYSTEMS GMBH 301
- 16.21.1 COMPANY SNAPSHOT 301
- 16.21.2 PRODUCT PORTFOLIO 301
- 16.21.3 RECENT DEVELOPMENT 301

17 QUESTIONNAIRE 302

18 RELATED REPORTS 306

LIST OF TABLES

TABLE 1 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 74
TABLE 2 EUROPE CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 3 EUROPE CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 75
TABLE 4 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION) 76
TABLE 5 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 77
TABLE 6 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION) 78
TABLE 7 EUROPE RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 78
TABLE 8 EUROPE ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 79
TABLE 9 EUROPE INSTRUMENT IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 10 EUROPE INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 80
TABLE 11 EUROPE SOFTWARE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 12 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 85
TABLE 13 EUROPE RNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 14 EUROPE DNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 15 EUROPE PNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 16 EUROPE OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 17 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 93
TABLE 18 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 94
TABLE 19 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 95
TABLE 20 EUROPE NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 95
TABLE 21 EUROPE HEMATOPOETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 96
TABLE 22 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 97
TABLE 23 EUROPE GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 24 EUROPE GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 98
TABLE 25 EUROPE INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 26 EUROPE INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 100
TABLE 27 EUROPE PERSONALIZED MEDICINE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 101
TABLE 28 EUROPE OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 101
TABLE 29 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 105
TABLE 30 EUROPE RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 31 EUROPE RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 106
TABLE 32 EUROPE CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 107
TABLE 33 EUROPE CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 108
TABLE 34 EUROPE COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 109
TABLE 35 EUROPE COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 109
TABLE 36 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION) 113
TABLE 37 EUROPE DIAGNOSTIC LABORATORIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 114
TABLE 38 EUROPE HOSPITALS & CLINICS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 115
TABLE 39 EUROPE PHARMACEUTICAL & BIOTECHNOLOGICAL COMPANIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 115
TABLE 40 EUROPE ACADEMIC & RESEARCH INSTITUTES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 116
TABLE 41 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 117
TABLE 42 EUROPE OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 117
TABLE 43 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 121
TABLE 44 EUROPE RETAIL SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 122
TABLE 45 EUROPE ONLINE SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 123
TABLE 46 EUROPE DIRECT TENDER IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 123
TABLE 47 EUROPE OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION) 124
TABLE 48 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 131
TABLE 49 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 132
TABLE 50 EUROPE CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 132
TABLE 51 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION) 132
TABLE 52 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 133
TABLE 53 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION) 133
TABLE 54 EUROPE RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 133
TABLE 55 EUROPE ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 56 EUROPE INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 57 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 134
TABLE 58 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 135
TABLE 59 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 135
TABLE 60 EUROPE NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 136
TABLE 61 EUROPE HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 136
TABLE 62 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 136
TABLE 63 EUROPE GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 137
TABLE 64 EUROPE INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 137
TABLE 65 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 137
TABLE 66 EUROPE RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 138
TABLE 67 EUROPE CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 138
TABLE 68 EUROPE COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 138
TABLE 69 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION) 139
TABLE 70 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 139
TABLE 71 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 72 GERMANY CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 73 GERMANY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION) 141
TABLE 74 GERMANY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 141
TABLE 75 GERMANY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION) 142
TABLE 76 GERMANY RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 142
TABLE 77 GERMANY ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 142
TABLE 78 GERMANY INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 143
TABLE 79 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 143
TABLE 80 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 143
TABLE 81 GERMANY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 144
TABLE 82 GERMANY NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 144
TABLE 83 GERMANY HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 144
TABLE 84 GERMANY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 145
TABLE 85 GERMANY GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 145
TABLE 86 GERMANY INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 145
TABLE 87 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 146
TABLE 88 GERMANY RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 146
TABLE 89 GERMANY CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 146
TABLE 90 GERMANY COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 147
TABLE 91 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION) 147
TABLE 92 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 147
TABLE 93 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 148
TABLE 94 U.K. CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 148
TABLE 95 U.K. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION) 149
TABLE 96 U.K. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 149
TABLE 97 U.K. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
TABLE 98 U.K. RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 150
TABLE 99 U.K. ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 150
TABLE 100 U.K. INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 151
TABLE 101 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 151
TABLE 102 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 151
TABLE 103 U.K. CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 152
TABLE 104 U.K. NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 152
TABLE 105 U.K. HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 152
TABLE 106 U.K. CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 153
TABLE 107 U.K. GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 153
TABLE 108 U.K. INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 153
TABLE 109 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 154
TABLE 110 U.K. RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 154
TABLE 111 U.K. CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 154
TABLE 112 U.K. COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 155
TABLE 113 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION) 155
TABLE 114 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 155
TABLE 115 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 156
TABLE 116 ITALY CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 156
TABLE 117 ITALY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION) 157
TABLE 118 ITALY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 157
TABLE 119 ITALY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
TABLE 120 ITALY RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158
TABLE 121 ITALY ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158
TABLE 122 ITALY INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 159
TABLE 123 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 159
TABLE 124 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 159
TABLE 125 ITALY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 160
TABLE 126 ITALY NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 160
TABLE 127 ITALY HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 160
TABLE 128 ITALY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 161
TABLE 129 ITALY GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 161
TABLE 130 ITALY INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 161
TABLE 131 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 162
TABLE 132 ITALY RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 162
TABLE 133 ITALY CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 162
TABLE 134 ITALY COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION) 163
TABLE 135 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION) 163
TABLE 136 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 163
TABLE 137 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 164
TABLE 138 FRANCE CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 164
TABLE 139 FRANCE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION) 165
TABLE 140 FRANCE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 165
TABLE 141 FRANCE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION) 166

LIST OF FIGURES

FIGURE 1 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION 40
FIGURE 2 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DATA TRIANGULATION 43
FIGURE 3 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DROC ANALYSIS 44
FIGURE 4 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 45
FIGURE 5 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY RESEARCH ANALYSIS 45
FIGURE 6 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: INTERVIEW DEMOGRAPHICS 46
FIGURE 7 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: MARKET APPLICATION COVERAGE GRID 48
FIGURE 8 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DBMR MARKET POSITION GRID 50
FIGURE 9 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: VENDOR SHARE ANALYSIS 52
FIGURE 10 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION 56
FIGURE 11 THE GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER AND HIGH FUNDING FOR RESEARCH ACTIVITIES IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET FROM 2023 TO 2030 57
FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET IN 2023 AND 2030 57
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET 65
FIGURE 14 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2022 72
FIGURE 15 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 73
FIGURE 16 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 73
FIGURE 17 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, LIFELINE CURVE 74
FIGURE 18 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2022 83
FIGURE 19 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 84
FIGURE 20 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, CAGR (2023-2030) 84
FIGURE 21 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, LIFELINE CURVE 85
FIGURE 22 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2022 91
FIGURE 23 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 92
FIGURE 24 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, CAGR (2023-2030) 92
FIGURE 25 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, LIFELINE CURVE 93
FIGURE 26 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2022 103
FIGURE 27 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2023-2030 (USD MILLION) 104
FIGURE 28 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, CAGR (2023-2030) 104
FIGURE 29 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, LIFELINE CURVE 105
FIGURE 30 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2022 111
FIGURE 31 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2023-2030 (USD MILLION) 112
FIGURE 32 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, CAGR (2023-2030) 112
FIGURE 33 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, LIFELINE CURVE 113
FIGURE 34 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2022 119
FIGURE 35 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 120
FIGURE 36 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 120
FIGURE 37 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 121
FIGURE 38 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SNAPSHOT (2022) 127
FIGURE 39 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022) 128
FIGURE 40 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2023 & 2030) 128
FIGURE 41 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022 & 2030) 129
FIGURE 42 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: PRODUCT TYPE (2023-2030) 130
FIGURE 43 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY SHARE 2022 (%) 261